Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Exelixis, Inc. (EXEL) has a Wall Street consensus price target of $44.40, based on estimates from 32 covering analysts. With the stock currently trading at $44.06, this represents a potential upside of +0.8%. The company has a market capitalization of $11.81B.
Analyst price targets range from a low of $30.00 to a high of $54.00, representing a 54% spread in expectations. The median target of $45.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, EXEL trades at a trailing P/E of 15.8x and forward P/E of 13.3x. The forward PEG ratio of 0.26 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +36.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $57.87, with bear and bull scenarios of $-13.87 and $142.78 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how EXEL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for EXEL is $44.4, close to the current price of $44.06 (0.8% implied move). Based on 32 analyst estimates, the stock appears fairly valued near current levels.
EXEL has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $44.4 implies 0.8% upside from current levels.
With a forward P/E of 13.2947x, EXEL trades at a relatively low valuation. The consensus target of $44.4 implies 0.8% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $54 for EXEL, while the most conservative target is $30. The consensus of $44.4 represents the median expectation. Our quantitative valuation model projects a bull case target of $143 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EXEL is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 16 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EXEL stock forecast based on 32 Wall Street analysts shows a consensus price target of $44.4, with estimates ranging from $30 (bear case) to $54 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $58, with bear/bull scenarios of $-14/$143.
Our quantitative valuation model calculates EXEL's fair value at $58 (base case), with a bear case of $-14 and bull case of $143. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
EXEL trades at a forward P/E ratio of 13.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 15.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
EXEL appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $44.4 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EXEL analyst price targets range from $30 to $54, a 54% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.4 consensus represents the middle ground. Our model's $-14-$143 range provides an independent fundamental perspective.